MedTrace Logo

Chimeric Antigen Receptor T Cells Targeting Glypican-3

NCT03884751 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-02-24

No results posted yet for this study

Summary

A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma

Conditions

Interventions

BIOLOGICAL

CAR-GPC3 T Cells

CAR-GPC3 T Cells injection

Sponsors & Collaborators

  • NanJing PLA 81 Hospital

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • RenJi Hospital

    collaborator OTHER

  • CARsgen Therapeutics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qin shukui, Pro · The 81st Hospital of PLA

  • Zhai bo, Pro · RenJi Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2021-05-28
Completion
2021-12-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03884751 on ClinicalTrials.gov